161 related articles for article (PubMed ID: 37489108)
1. Platelet-lymphocyte ratio and lymphocyte-monocyte ratio in inflammatory bowel disease and disease activity: A systematic review and meta-analysis.
Gao L; Zhan Y; Hu X; Liao S
Scott Med J; 2023 Aug; 68(3):101-109. PubMed ID: 37489108
[TBL] [Abstract][Full Text] [Related]
2. Unveiling the Ghrelin and Obestatin Roles in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis Assessing Their Pathogenic Implications and Biomarker Utility.
Khalaji A; Babajani N; Amirsardari Z; Saeedian B; Peiman S; Berger NA; Behnoush AH
Inflamm Bowel Dis; 2024 Apr; 30(4):629-640. PubMed ID: 37669127
[TBL] [Abstract][Full Text] [Related]
3. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.
Sinopoulou V; Gordon M; Akobeng AK; Gasparetto M; Sammaan M; Vasiliou J; Dovey TM
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013531. PubMed ID: 34844288
[TBL] [Abstract][Full Text] [Related]
4. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
[TBL] [Abstract][Full Text] [Related]
5. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
Ng SC; Shi HY; Hamidi N; Underwood FE; Tang W; Benchimol EI; Panaccione R; Ghosh S; Wu JCY; Chan FKL; Sung JJY; Kaplan GG
Lancet; 2017 Dec; 390(10114):2769-2778. PubMed ID: 29050646
[TBL] [Abstract][Full Text] [Related]
6. Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort.
Greuter T; Porchet F; Braga-Neto MB; Rossel JB; Biedermann L; Schreiner P; Scharl M; Schoepfer AM; Safroneeva E; Straumann A; Rogler G; Vavricka SR
United European Gastroenterol J; 2020 Dec; 8(10):1196-1207. PubMed ID: 33276710
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study.
Ferreiro-Iglesias R; Barreiro-de Acosta M; López-Díaz J; Bastón Rey I; Domínguez-Muñoz JE
Rev Esp Enferm Dig; 2022 Jan; 114(1):10-15. PubMed ID: 33486959
[TBL] [Abstract][Full Text] [Related]
8. Increased monocyte abundance as a marker for relapse after discontinuation of biologics in inflammatory bowel disease with deep remission.
Kwon Y; Kim YZ; Choe YH; Kim MJ
Front Immunol; 2022; 13():996875. PubMed ID: 36389755
[TBL] [Abstract][Full Text] [Related]
9. INTERACTIONS AMONG INTERLEUKIN-6, C-REACTIVE PROTEIN AND INTERLEUKIN-6 (-174) G/C POLYMORPHISM IN THE PATHOGENESIS OF CROHN'S DISEASE AND ULCERATIVE COLITIS.
Takač B; Mihaljević S; Glavaš-Obrovac L; Kibel A; Suver-Stević M; Canecki-Varžić S; Samardžija M; Rajkovac I; Kovač D; Štefanić M
Acta Clin Croat; 2020 Mar; 59(1):67-80. PubMed ID: 32724277
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
[TBL] [Abstract][Full Text] [Related]
11. Cytokine production in patients with inflammatory bowel disease.
Nakamura M; Saito H; Kasanuki J; Tamura Y; Yoshida S
Gut; 1992 Jul; 33(7):933-7. PubMed ID: 1644332
[TBL] [Abstract][Full Text] [Related]
12. Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
Naseer M; Poola S; Ali S; Samiullah S; Tahan V
Curr Clin Pharmacol; 2020; 15(3):216-233. PubMed ID: 32164516
[TBL] [Abstract][Full Text] [Related]
13. Mean platelet volume: a useful marker of inflammatory bowel disease activity.
Kapsoritakis AN; Koukourakis MI; Sfiridaki A; Potamianos SP; Kosmadaki MG; Koutroubakis IE; Kouroumalis EA
Am J Gastroenterol; 2001 Mar; 96(3):776-81. PubMed ID: 11280550
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of selective granulocyte and monocyte apheresis for inflammatory bowel disease: A meta-analysis.
Liu Z; Jiang X; Sun C
Eur J Intern Med; 2016 Dec; 36():e26-e27. PubMed ID: 27614377
[No Abstract] [Full Text] [Related]
15. T lymphocyte subsets in inflammatory bowel disease: peripheral blood.
Selby WS; Jewell DP
Gut; 1983 Feb; 24(2):99-105. PubMed ID: 6221976
[TBL] [Abstract][Full Text] [Related]
16. Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease.
Mazlam MZ; Hodgson HJ
Gut; 1994 Jan; 35(1):77-83. PubMed ID: 8307455
[TBL] [Abstract][Full Text] [Related]
17. Elevated ectodomain of type 23 collagen is a novel biomarker of the intestinal epithelium to monitor disease activity in ulcerative colitis and Crohn's disease.
Manon-Jensen T; Sun S; Lindholm M; Domislović V; Giuffrida P; Brinar M; Mazza G; Pinzani M; Krznarić Z; Di Sabatino A; Karsdal MA; Mortensen JH
United European Gastroenterol J; 2021 Mar; 9(2):268-278. PubMed ID: 33351719
[TBL] [Abstract][Full Text] [Related]
18. Familial occurrence and inheritance studies in inflammatory bowel disease.
Binder V; Orholm M
Neth J Med; 1996 Feb; 48(2):53-6. PubMed ID: 8819799
[TBL] [Abstract][Full Text] [Related]
19. Plasma transforming growth factor-beta1 level in inflammatory bowel disease.
Kiliç ZM; Ayaz S; Ozin Y; Nadir I; Cakal B; Ulker A
Turk J Gastroenterol; 2009 Sep; 20(3):165-70. PubMed ID: 19821197
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of transrectal endoscopic ultrasound elastography in inflammatory bowel disease.
Rustemovic N; Cukovic-Cavka S; Brinar M; Radić D; Opacic M; Ostojic R; Vucelic B
BMC Gastroenterol; 2011 Oct; 11():113. PubMed ID: 22014337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
